Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 17/20 | 0.77 |
| ▸ | CDK9 | P50750 | 17/20 | 0.77 |
| ▸ | BACE1 | P56817 | 3/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4101898 | 0.87 | CCNT1 (1.00) | CCNT1CDK9BACE1 | |
| SCHEMBL14050409 | 0.85 | CCNT1 (0.57) | CCNT1CDK9BACE1 | |
| SCHEMBL4097348 | 0.83 | CCNT1 (0.78) | CCNT1CDK9BACE1 | |
| SCHEMBL11898137 | 0.78 | CCNT1 (0.69) | CCNT1CDK9BACE1 | |
| SCHEMBL4102047 | 0.78 | CCNT1 (0.69) | CCNT1CDK9 | |
| SCHEMBL4108631 | 0.77 | BACE1 (0.81) | CCNT1CDK9BACE1 | |
| SCHEMBL4109231 | 0.76 | CCNT1 (0.77) | CCNT1CDK9BACE1 | |
| SCHEMBL4109321 | 0.75 | BACE1 (1.00) | CCNT1CDK9BACE1 | |
| SCHEMBL4103718 | 0.75 | BACE1 (0.78) | CCNT1CDK9BACE1 | |
| SCHEMBL4113685 | 0.74 | BACE1 (0.74) | CCNT1CDK9BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2748331-B1 | SUSCEPTIBILITY TO SELECTIVE CDK9 INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2016-03-02 | — | — | EP | claimed |
| US-20150329537-A2 | CDK9 INHIBITORS IN THE TREATMENT OF MIDLINE CARCINOMA | LEADDISCOVERY CENTER GMBH (DE) | 2015-11-19 | — | — | US | claimed |
| US-20140303167-A1 | CDK9 INHIBITORS IN THE TREATMENT OF MIDLINE CARCINOMA | LEAD DISCOVERY CENTER GMBH (DE) | 2014-10-09 | — | — | US | claimed |
| US-20140287454-A1 | SUSCEPTIBILITY TO SELECTIVE CDK9 INHIBITORS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2014-09-25 | — | — | US | claimed |
| EP-2561867-A1 | CDK9 inhibitors in the treatment of midline carcinoma | Lead Discovery Center GmbH (DE) | 2013-02-27 | — | — | EP | claimed |
| EP-2562265-A1 | Susceptibility to selective CDK9 inhibitors | Lead Discovery Center GmbH (DE) | 2013-02-27 | — | — | EP | claimed |
| EP-1678147-B1 | PHARMACEUTICALLY ACTIVE 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS MODULATORS OF PROTEIN KINASES | LEAD DISCOVERY CENTER GMBH (DE) | 2012-08-08 | — | — | EP | claimed |
| EP-2748331-B1 | SUSCEPTIBILITY TO SELECTIVE CDK9 INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2016-03-02 | — | — | EP | disclosed |
| US-20150329537-A2 | CDK9 INHIBITORS IN THE TREATMENT OF MIDLINE CARCINOMA | LEADDISCOVERY CENTER GMBH (DE) | 2015-11-19 | — | — | US | disclosed |
| US-20140303167-A1 | CDK9 INHIBITORS IN THE TREATMENT OF MIDLINE CARCINOMA | LEAD DISCOVERY CENTER GMBH (DE) | 2014-10-09 | — | — | US | disclosed |
| US-20140287454-A1 | SUSCEPTIBILITY TO SELECTIVE CDK9 INHIBITORS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2014-09-25 | — | — | US | disclosed |
| EP-2747755-A1 | CDK9 INHIBITORS IN THE TREATMENT OF MIDLINE CARCINOMA | Lead Discovery Center GmbH (DE) | 2014-07-02 | — | — | EP | disclosed |
| WO-2013026874-A1 | CDK9 INHIBITORS IN THE TREATMENT OF MIDLINE CARCINOMA | LEAD DISCOVERY CENTER GMBH (DE) | 2013-02-28 | — | — | WO | disclosed |
| EP-2562265-A1 | Susceptibility to selective CDK9 inhibitors | Lead Discovery Center GmbH (DE) | 2013-02-27 | — | — | EP | disclosed |
| EP-2561867-A1 | CDK9 inhibitors in the treatment of midline carcinoma | Lead Discovery Center GmbH (DE) | 2013-02-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329537-A2 | CDK9 INHIBITORS IN THE TREATMENT OF MIDLINE CARCINOMA | CDK9, CDK19, CDKN1A | CCNT1 41/4885CDK9 1/4885BACE1 2565/4885 |
| US-20140303167-A1 | CDK9 INHIBITORS IN THE TREATMENT OF MIDLINE CARCINOMA | CDK9, CDK19, CDKN1A | CCNT1 41/4885CDK9 1/4885BACE1 2565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.